In December 2003, The United States FDA granted GlaxoSmithKline's compound GW572016(Lapatinib) fast-track status for treatment of certain patients with refractory advanced or metastatic breast cancer who have failed previous therapies.
Clinical trials testing this oral investigational medication are ongoing at more than 100 sites throughout the country, with the goal of recruiting more than 600 women for the studies.
If you are interested in participating in these studies, click the link on our Home Page or go to:
www.4breastcancertrials.com
We share the common goal of finding better ways to treat breast cancer. Clinical trials are crucial to this process.
Hugs and well wishes
Christine